PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1603239
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1603239
In terms of value, the bioresorbable polymers market is estimated to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6%. Favorable regulations and policies by the government towards healthcare industry are positively influencing the bioresorbable polymers market. Various countries have created regulations that encourage manufacturers to increase biocompatibility & biodegradability of medical devices like orthopedic devices. These changes promote the creation of bioresorbable polymers. New technologies for the surgical implants are driving the demand for bioresorbable polymers. This further encourages businesses to invest in the bioresorbable polymers market.
Scope of the Report | |
---|---|
Years Considered for the Study | 2019-2029 |
Base Year | 2023 |
Forecast Period | 2024-2029 |
Units Considered | Value (USD Million) and Volume (Unit) |
Segments | Type, Application, and Region |
Regions covered | Asia Pacific, Europe, North America, Middle East & Africa, and South America |
"PCL type segment is projected to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period"
PCL type segment is estimated to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period. This demand is primarily due to its demand in drug delivery systems. The properties of biocompatibility and flexibility make PCL flexible and capable for use in any drug delivery format, such as injectable microparticles, implantable devices, and capsules. Compatibility with other bioresorbable polymers brings it as the first choice for customized formulations in advanced therapeutic systems.
"Drug delivery was the second largest end-use industry of bioresorbable polymers market, in terms of value, in 2023."
Drug delivery segment stands as the second-largest application in the bioresorbable polymers market. The demand is fueled by the need of controlled, targeted, and sustained-release drug systems, resulting in improved patient outcomes. Bioresorbable polymers are also widely employed in the preparation of implantable drug matrices and capsules to provide a slow and controlled release of therapeutic agents over time. This avoids the need for re-dose, thus significantly reducing discomfort to the patient. Their biocompatibility ensures that these polymers degrade safely within the body, well in line with the increasing trend by the medical industry towards innovative, patient-centered care solutions. With the desire for advanced drug delivery systems all over the world on the rise, bioresorbable polymers are among the most important choices when making efficient and effective therapeutic solutions.
"Europe was the second largest region in the bioresorbable polymers market, in terms of value."
Europe was the second-largest region in the bioresorbable polymers market, in terms of value, in 2023. The bioresorbable polymers market in the region is comparatively mature, growing slower than the developing markets in the Asia-Pacific region and South America. The demand of bioresorbable polymers in the European region is primarily due to the increasing prevalence of chronic diseases such as cancers, cardiovascular diseases, orthopedic disorders, and neurological conditions. Bariatric, trauma, orthopedic, and cardiovascular surgical procedures are also on the rise in Europe. The region has developed a strong health care infrastructure and increased the level of advanced medical research further, which has clearly enhanced this market for bioresorbable polymers offered as sustainable and biocompatible solutions for implants and drug delivery systems. Additionally, the support by regulatory towards biodegradable material-based medical devices helps to spread across the European market.
The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).
Research Coverage
This report segments the market for bioresorbable polymers based on type, application, and region and provides estimations of value (USD Million) for the overall market size across various regions. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, services, and key strategies, associated with the market for bioresorbable polymers.
Reasons to Buy this Report
This research report is focused on various levels of analysis - industry analysis (industry trends), market share analysis of top players, and company profiles, which together provide an overall view of the competitive landscape, emerging and high-growth segments of the bioresorbable polymers market; high-growth regions; and market drivers, restraints, and opportunities.